Partial hepatectomy is a first-line treatment for hepatocellular carcinoma.Within 2 weeks following partial hepatectomy,specific molecular pathways are activated to promote liver regeneration.Nevertheless,residual mic...Partial hepatectomy is a first-line treatment for hepatocellular carcinoma.Within 2 weeks following partial hepatectomy,specific molecular pathways are activated to promote liver regeneration.Nevertheless,residual microtumors may also exploit these pathways to reappear and metastasize.Therapeutically targeting molecules that are differentially regulated between normal cells and malignancies,such as fibrinogen-like protein 1(FGL1),appears to be an effective approach.The potential functions of FGL1 in both regenerative and malignant cells are discussed within the ambit of this review.While FGL1 is normally elevated in regenerative hepatocytes,it is normally downregulated in malignant cells.Hepatectomy does indeed upregulate FGL1 by increasing the release of transcription factors that promote FGL1,including HNF-1α and STAT3,and inflammatory effectors,such as TGF-β and IL6.This,in turn,stimulates certain proliferative pathways,including EGFR/Src/ERK.Hepatectomy alters the phase transition of highly differentiated hepatocytes from G0 to G1,thereby transforming susceptible cells into cancerous ones.Activation of the PI3K/Akt/mTOR pathway by FGL1 allele loss on chromosome 8,a tumor suppressor area,may also cause hepatocellular carcinoma.Interestingly,FGL1 is specifically expressed in the liver via HNF-1α histone acetylase activity,which triggers lipid metabolic reprogramming in malignancies.FGL1 might also be involved in other carcinogenesis processes such as hypoxia,epithelial-mesenchymal transition,immunosuppression,and sorafenib-mediated drug resistance.This study highlights a research gap in these disciplines and the necessity for additional research on FGL1 function in the described processes.展开更多
基金supported by the Doctoral Research Fund of Hubei University of Science and Technology,with project number Q201810.
文摘Partial hepatectomy is a first-line treatment for hepatocellular carcinoma.Within 2 weeks following partial hepatectomy,specific molecular pathways are activated to promote liver regeneration.Nevertheless,residual microtumors may also exploit these pathways to reappear and metastasize.Therapeutically targeting molecules that are differentially regulated between normal cells and malignancies,such as fibrinogen-like protein 1(FGL1),appears to be an effective approach.The potential functions of FGL1 in both regenerative and malignant cells are discussed within the ambit of this review.While FGL1 is normally elevated in regenerative hepatocytes,it is normally downregulated in malignant cells.Hepatectomy does indeed upregulate FGL1 by increasing the release of transcription factors that promote FGL1,including HNF-1α and STAT3,and inflammatory effectors,such as TGF-β and IL6.This,in turn,stimulates certain proliferative pathways,including EGFR/Src/ERK.Hepatectomy alters the phase transition of highly differentiated hepatocytes from G0 to G1,thereby transforming susceptible cells into cancerous ones.Activation of the PI3K/Akt/mTOR pathway by FGL1 allele loss on chromosome 8,a tumor suppressor area,may also cause hepatocellular carcinoma.Interestingly,FGL1 is specifically expressed in the liver via HNF-1α histone acetylase activity,which triggers lipid metabolic reprogramming in malignancies.FGL1 might also be involved in other carcinogenesis processes such as hypoxia,epithelial-mesenchymal transition,immunosuppression,and sorafenib-mediated drug resistance.This study highlights a research gap in these disciplines and the necessity for additional research on FGL1 function in the described processes.
